Name of License: NovMetaPharma Co., Ltd.
Summary: The present invention relates to the use of Cyclo-Z to stimulate cell growth and immune system components, and to modulate levels of several components involved in inflammation and autoimmune diseases, which may be helpful in fighting infectious agents as well as be useful in treating allergies, inflammation, and autoimmune diseases.
Tech Name:
Compositions and methods for prevention and treatment of immune deficiency and inflammation
Dates: Comments must be received by March 15, 2021
Address: Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420
For Further Information Contact: Send comments to Dr. Lee A. Sylvers, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (813) 505-6989 (this is not a toll-free number), Email: [email protected]
Supplementary Information: The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention to NovMetaPharma Co., Ltd. as they have submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.